Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Cancer Mechanisms and Therapy, and Lung Cancer Treatments and Mutations.
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer
An international report on bacterial communities in esophageal squamous cell carcinoma
Discovering dominant tumor immune archetypes in a pan-cancer census
Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
Ferrous Iron-Dependent Pharmacology
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa
Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma
Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma
Stromal cues regulate the pancreatic cancer epigenome and metabolome
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination
Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Erratum to: Modeling precision treatment of breast cancer
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes